



U.S.I. Numidio Quadrato, Via Tuscolana 703 - Roma

CHART OF SERVICES

with Guide to Services and Charter of Patient Rights






Legal Representative: Dr. Giovanni Torre; Technical Director of the Clinical Analysis Laboratory: Dr. Vincenzo Genovese
Regional Accreditation Resolution: *DCA* U00056 del 04/03/2013

Index

1. PRESENTATION	4
2. QUALITY AND CLINICAL RISK MANAGEMENT	4
3. INFORMED CONSENT, RIGHTS AND DUTIES OF THE PATIENT	5
4. USERPROTECTION, SUGGESTIONS AND COMPLAINTS	5
5. ACCESS TO BENEFITS AND COSTS	6
6. THE WITHDRAWAL OF REPORTS.....	6
7. PERFORMANCE AND WAITING TIMES	6
CLINICAL LABORATORY ANALYSIS	7
<i>Booking and access</i>	7
<i>Clinical analysis services provided under the accreditation regime with the NHS</i>	7
<i>Private clinical analysis services provided</i>	8
8. LOCATION AND CONTACT DETAILS	12
9. OPENING DAYS AND HOURS.....	12

Attachments, which can be requested

-  *Rates of services, under private regime or accreditation with the NHS*
-  *Guides and information brochures on health services and benefits, in private or accreditation with the NHS*
-  *Flowchart*

Dear Madam, Dear Sir,

In welcoming you, we present the "Service Charter" of our health facility, drawn up in accordance with the reference regulations including DCA 311/2014 Regione Lazio, in which we report a series of information that we consider useful for patients and their cares.

La Carta Le will allow you to learn more about our structure and providing you with information on the health offer, on the specialized services provided and on the relative methods of access.

The hope is that, also through the reading of the Charter of Services, you can appreciate our constant commitment to concretely translate the values and principles that feed our work, which identifies in the "centrality" of the Patient the most important objective, in the face of diagnosis and therapies however at the forefront in the medical field, in strict compliance with the principles of Evidence-Based Medicine (EBM).

It should also be noted that this Service Charter refers to the Guides to the Services provided. In particular, for the main services provided, complete information brochures have been prepared, but easy and quick to consult, available at the appropriate exhibitors located at the waiting rooms.

Finally, we invite you to point out ideas and suggestions, which can contribute to the continuous improvement of the organization and efficiency of our health facility.

Technical Director of the Clinical Analysis Laboratory

Dr. Vincenzo Genovese

1. PRESENTATION

U.S.I. (Unione Sanitaria Internazionale) S.p.A. was founded in 1953 by Dr. Luigi Sperone, becoming over the years the most present health reality in Rome, with a network of 24 health facilities widely distributed throughout the metropolitan area and more than 500 specialized operators.

U.S.I. Numidio Quadrato is located in Via Tuscolana 703, is extended on one level and provides the following health services, subsequently deepened

- Clinical Laboratory Analysis.

The structure is accredited with the National Health Service (NHS or, in Italian, SSN/SSR) of the Lazio Region (the regional accreditation resolutions are shown at the foot of the title page of this service charter). The numerable benefits are provided in agreement with the NHS or with **private** bodies, as detailed in the following chapters.

The facilities of the U.S.I. Group provide an integrated, wide and advanced healthcare offer in the field of Clinical Laboratory Analysis (Clinical Chemistry, Molecular Biology, Cyto-Histopathology), Diagnostic Imaging (Magnetic Resonance, CT, Digital Radio diagnostics, PET, Ultrasound), Specialized and Occupational Medicine, cancer prevention and treatment.

The **U.S.I. Group** consists of the following health facilities, all located in the municipality of Rome:

- **USI PRATI**, via Virginio Orsini, 18
- **AXA-PALOCCO**, via Eschilo, 191
- **BORGHESIANA**, via Casilina, 1838
- **COLLATINO**, viale della Serenissima, 22
- **COLLE-PRENESTINO**, via Mirabella Eclano 27
- **CINECITTÀ**, viale Bruno Rizzieri, 203
- **EUR-LAURENTINA**, via V. Cerulli, 2/b
- **EUR-SERAFICO**, via P. di Dono, 9
- **EUR-MARCONI**, viale G. Marconi, 139
- **FURIO CAMILLO**, via Cerreto di Spoleto, 9/21
- **NUMIDIO QUADRATO**, Via Tuscolana, 703
- **PIAZZA BOLOGNA**, via G. Squarcialupo, 17/b
- **CASA DI CURA MARCO POLO S.r.l.**, viale Marco Polo, 41, 00154 Roma (Ostiense). The only private single-specialist oncology clinic in the Lazio Region, it offers oncological diagnosis and treatment courses in the specialties of Radiotherapy, Medical Oncology, Nuclear Medicine with Radiometabolic Therapy.
- **PIAZZA BOLOGNA**, via G. Squarcialupo, 36
- **PIAZZA VITTORIO**, via Machiavelli, 22
- **PIETRALATA**, via dei Durantini, 362
- **POLICLINICO**, viale Regina Margherita, 279
- **PIAZZA MAZZINI**, viale Angelico, 39
- **SERPENTARA**, via G. Pacchiarotti, 95
- **TRIESTE**, Corso Trieste, 22
- **USI DOC - PRATI**, via Virginio Orsini, 18/27A
- **USI DOC - TUSCOLANA**, via Tuscolana 212/F
- **USI DOC**, Viale del Lido, 5/A
- **LIDO DI OSTIA - Villa del Lido S.r.l.**, viale del Lido, 3

2. QUALITY AND CLINICAL RISK MANAGEMENT

U.S.I. applies since its foundation advanced quality control and management systems of all health services, which are provided in compliance with guidelines and analytical methods recognized by the scientific community.

The company's "vision", "mission" and quality policies are aimed at providing high-quality health services, using advanced biomedical technologies, the involvement and competence of staff, correct communication, compliance with mandatory requirements and volunteers, health promotion and protection of patient rights, risk prevention techniques and continuous improvement.

Business processes are monitored through indicators that also refer to: outcomes and characteristics of performance; waiting times; rate of repetition of withdrawals; analytical accuracy; satisfaction of users, patients and Stakeholders; incidence of "non-conformities", complaints, accidents or "quasi-accidents" in the field of Health and Safety in the workplace, adverse events or "sentinel", the effectiveness of the actions consequently undertaken.

The controls include participation in quality planning and quality programs at national and international level.

All U.S.I. Group properties are certified according to the international standard UNI EN ISO 9001:2015 issued by a prestigious certification body. The laboratory of U.S.I. Prati has obtained the IMQ LAB-MED certification, which provides for compliance with particularly strict standards in terms of Quality and accuracy of the analytical result.

The health facility is also accredited with the Health Service of the Lazio Region (NHS or SSN/SSR), on the basis of the Additional requirements for the accreditation of health facilities, governed by the reference legislation.

Any elements of clinical risk are evaluated at all stages of the patient's health path.

3. INFORMED CONSENT, RIGHTS AND DUTIES OF THE PATIENT

U.S.I. Numidio Quadrato actively guarantees the following patient's rights:

- to be informed in an appropriate and comprehensible way by the health personnel on their state of health and on characteristics, risks, alternatives in relation to the health services that concern them, expressing their consent or denial in advance;
- to be assisted with attention, impartiality, with respect for one's own time, one's own dignity, one's own needs and philosophical or religious convictions;
- transparency and simplicity of administrative paths;
- the confidentiality and confidentiality of the health services received;
- safety and quality of health services;
- to the complaint and to an appropriate response.

Users are required to always inform the acceptance or health staff of the structure of any needs related to their health conditions, to prevent any risk of adverse or unwanted events (e.g. in case of problems related to patient mobility or therapies already in progress).

It recalls the importance of user behavior based on respect and understanding of the rights of other users and patients, as well as trust and collaboration towards health personnel.

Compliance with the schedules of the services booked is required, informing in case of delays or cancellation.

It is also recalled that smoking is strictly forbidden in the structure.

4. USERPROTECTION, SUGGESTIONS AND COMPLAINTS

Suggestions or complaints can be made by users through the **website www.usi.it**, on "carte blanche" or on the Satisfaction *Questionnaire* that can be collected at the waiting rooms of the facilities and to be inserted in the appropriate containers or to be sent by ordinary mail, e-mail or fax to the addresses indicated in this Service Charter.

The functions in charge and the collection of complaints are Secretary and each signed report will be ensured a response as soon as possible and in any case no later than 30 days from the presentation of the same, except for important obstacle causes. *la Direzione Sanitaria*.

It is also possible to lodge a complaint with the TRIBUNALE PER I DIRITTI DEL MALATO (Viale Angelico, 28, 00195 Rome, Tel. 06/3729924, 06/6385881 e-mail: roma@cittadinanzattiva.it).

5. ACCESS TO BENEFITS AND COSTS

- To access services in **accreditation with the NHS**, a request from the attending physician (binding NHS on "pink prescription" or electronic) is required, which also indicates any exemptions. As a rule, the commitment is valid for one year and contains up to 8 benefits for the same branch. For services in agreement with the NHS, the same rates are applied as for public facilities.
- To access services under a private regime, or in agreement with private bodies, a request from the attending physician or specialist may be necessary (refer to the following chapters for specific services).
- At the acceptance secretariats or by contacting the unique number **06 32868.1** information is provided on times, costs and methods of preparation for the health services provided and estimates can be requested. On the **website www.usi.it**, special "information" can also be consulted for the correct preparation of the patient for the required health services.
- It is possible to pay for the services by cash, bank checks, bancomat or bankcards.
- For any **emergencies**, the health personnel concerned evaluates the execution of the analyzes in the time required, establishing the time of release of the complete or partial report in the shortest possible technical time.
- The health structure implements health promotion initiatives, preparing information campaigns and specific or multidisciplinary health packages in relation to the major diseases treated. Health packages may include medical, radiological or clinical analysis services. It is possible to refer to the website or request information during the acceptance phase in relation to any initiatives in progress.
- Staff are available at the property who can communicate in **English** and/or other foreign languages. An English version of the Service Charter is available, which can be requested at the Segreteria.
- The structure guarantees health services that take into account the religious convictions or cultural aspects of the Patient. Please point out any needs during the acceptance phase to agree on the appropriate methods.
- At all the health facilities of the U.S.I. Group there are preferential bears for patients in conditions **of fragility** (e.g. reduced mobility or pregnancy) or affected by oncological pathologies.
- In consideration of the **Covid-19** health emergency, access to the structure is regulated in accordance with the reference legislation, as indicated in the appropriate signs. In the structure are available detergents-disinfectants for the hands and any additional protective aids.
- Further information on how to book and access can be found in the paragraphs on specific services.

6. THE WITHDRAWAL OF REPORTS

The collection of the reports and any attachments can be made at the Acceptance or "on-line", Secretary activating the relative service at the time of acceptance.

Please note that the reports can only be delivered:

- to the person directly concerned or delegated person (who must present his identity document, the proxy and a copy of the identity document of the delegating);
- in the case of a minor, to the person concerned with an identity document or to the person exercising parental authority, equipped with an identity document;
- to the guardian or curator with an identity document and the necessary documentation.

As a rule, duplicates of digital reports can be released immediately, for any duplicates of paper reports, the ordinary times defined according to the type of report are to be considered (see chapter 7). However, request information from the Acceptance Secretariat.

7. PERFORMANCE AND WAITING TIMES

All health services provided at the health facility and listed and detailed in the following chapters, are authorized and in the cases indicated, accredited, based on the accreditation resolutions reported on the title page of this service charter.

In the following chapters are detailed for each branch of the specialist, under accreditation with the NHS or private:

- Name of the Reference Manager
- Information on how to book and access
- Information on the services provided and the related waiting times for booking, access and reporting.

CLINICAL LABORATORY ANALYSIS

Technical Director of the Laboratory of Clinical Analysis: Dr. Vincenzo Genovese

Booking and access

- To access services in accreditation with the NHS, a request from the attending physician is required (demanding NHS on "pink prescription" or electronic).
- Blood samples are made without reservation by going from 7.00 to 11.00, every day including Saturday, directly at the reception office of our structure.
- Consult the website www.usi.it or la SegreteriaAccettazione for information on the correct preparation of the Patient for the health services requested.
- Withdrawals are made at home, la SegreteriaAccettazione is available for the related information.
- It is specified that at the laboratory of the structure the "pre" and "post-analytical" phases of the examinations are carried out. The analytical phase of the sample is carried out in the reference "HUB" laboratory of the U.S.I. Group. Relative information is always reported in the reports, which indicate the laboratory that performed the analysis.

Clinical analysis services provided under the accreditation regime with the NHS

- 17KS URINARY (MG/24H)	- CA 50	- COMPLETE BLOOD COUNT AND FORMULA - 3rd PR.
- 17OH HYDROXYCORTICOSTEROIDS	- CALCEMIA	- COMPLETE BLOOD COUNT AND FORMULA - 4th PR.
- 17OH PROGESTERONE	- IONIZED CALCIUM	- COMPLETE BLOOD COUNT AND FORMULA - 5th PR.
- 17OH PROGESTERONE - 2nd WITHDRAWAL	- CALCITONIN	- COMPLETE BLOOD COUNT AND FORMULA - 6th PR.
- AB ANTI-INSULIN	- CALCITONIN - 2nd SAMPLING	- COMPLETE BLOOD COUNT AND FORMULA - 7th PR.
- AB ANTI-MICROSOMIAL	- CALCITONIN - 3rd SAMPLING	- COMPLETE BLOOD COUNT AND FORMULA - 8th PR.
- AB ANTI-THYROID PEROXIDASE (ECL)	- CALCURIARIA	- HAEMOGLOBIN
- AB ANTI-THYROGLOBULIN (ECL)	- CALCULATION (EXAM)	- ANTIMYCOGRAM + ABG EXAMINATION
- FOLIC ACID (ECL)	- CANDIDA ALBICANS (CULTURE)	- CULTURE EXAMINATION + ABG
- ACTH	- CEA (ECL)	- CULTURE EXAMINATION WITH ANTI BIOGRAM
- ACTH - 2nd WITHDRAWAL	- CK-MB (37°)	- MICROSCOPIC EXAMINATION
- ALDOLASE (37°)	- CHLOREMIIA	- ESTRIOL IN PREGNANCY
- ALDOSTERONE	- CHLORIDES	- URINARY ESTRIOL
- ALDOSTERONE - 2nd WITHDRAWAL	- TOTAL CHOLESTEROL	- RHEUMATOID FACTOR
- URINARY ALDOSTERONE	- PROSTATE SECRET CULTURE	- FECES (COMPLETE EXAMINATION)
- ALPHAFETOPROTEIN (ECL)	- URETHRAL SECRETORY CULTURE	- FECES (PEST RESEARCH)
- ALPHAFETOPROTEIN IN PREGNANCY	- VAGINAL CULTURE + ABG	- FECES (OCCULT BLOOD)
- URINARY ALPHAFETOPROTEIN	- COPROCULTURE	- FERRITIN (ECL)
- AMYLASEMIA (37°)	- COPROCULTURE FOR SALMONELLA	- FIBRINOGEN
- AMILASURIA	- CORTISOL - 2nd SAMPLE (ECL)	- ACID PHOSPHATASE
- AMMONIEMIA	- CORTISOL (ECL)	- ALKALINE PHOSPHATASE (37°)
- ANDROSTENEDIONE DELTA 4	- CORTISOL CIRC ADIANO	- PHOSPHATURIA
- ANDROSTENEDIONE DELTA 4 - 2nd WITHDRAWAL	- URINARY CORTISOL (ECL)	- PHOSPHOREMIA P
- ANGIOTENSIN	- CREATININEMIA	- FSH - 2nd WITHDRAWAL
- ANGIOTENSIN - 2nd SAMPLE	- FSH CURVE	- FT3 (ECL)
- ANTISTREPTOLYSIN	- GLYCEMIC CURVE	- FT3 (ECL) - 2nd WITHDRAWAL
- PROTHROMBIN + INR ACTIVITY	- INSULIN-STIM CURVE. GLUCOSE (ECL)	- FT3 (ECL) - 3rd WITHDRAWAL
- PROTHROMBIN ACTIVITY + INR 2nd PR.	- LH CURVE (ecl) - GNRH STIMULUS	- FT3 (ECL) - 4th WITHDRAWAL
- PROTHROMBIN ACTIVITY + INR 3rd PR.	- PEPTIDE CURVE C	- FT3 (ECL) - 5th WITHDRAWAL
- PROTHROMBIN ACTIVITY + INR 4° PR.	- DHT DEHYDROEPIANDROSTERONE	- FT4 (ECL)
- PROTHROMBIN ACTIVITY + INR 5° PR.	- DHT DEHYDROEPIANDROSTERONE - 2nd WITHDRAWAL	- GAMMAGLUTAMYLTRANSFERASE (37°)
- PROTHROMBIN ACTIVITY + INR 6° PR.	- DEA-SULFATE	- GASTRIN
- PROTHROMBIN ACTIVITY + INR 7° PR.	- DEA-SULFATE - 2nd SAMPLE	- GASTRIN - 2nd WITHDRAWAL
- PROTHROMBIN ACTIVITY + INR 8° PR.	- DIGOXIN (ECL)	- GH
- AZOTEMIA (UREA NITROGEN)	- DIGOXIN (ECL) - 2nd WITHDRAWAL	- GH - 2nd WITHDRAWAL
- BETA- 2 BLOOD MICROGLOBULIN - 2nd SAMPLING	- E1 - ESTRONE	- GLYCEMIA
- DIRECT BILIRUBINEMIA	- E1 - ESTRONE - 2nd WITHDRAWAL	- TOTAL GLYCOSURIA
- TOTAL BILIRUBINEMIA	- E3 - ESTRIOL	- WHITE BLOOD CELLS
- TOTAL AND FRACTIONAL BILIRUBINEMIA	- E3 - ESTRIOL - 2nd SAMPLING	- RED BLOOD CELLS
- TOTAL AND FRACTIONAL BILIRUBINEMIA - 2nd part	- HEMATOCRIT	
- CA 125 (ECL)	- HEMOCULTURE	
- CA 15-3 (ECL)	- COMPLETE BLOOD COUNT AND FORMULA	
- CA 19-9 (ECL)	- COMPLETE BLOOD COUNT AND FORMULA - 2nd PR.	

- GLUCAGON
- GLUCAGON - 2nd WITHDRAWAL
- HAV-AB
- HAV-AB IGM
- HAV-IGM
- HBCAB - IGM
- HBCAB (ANTIBODY ANTIBODY)
- HBEAB (ANTI-E ANTIBODY)
- HBSAB (ANTI-S ANTIBODY)
- HBSAG (ANTIGEN AUSTRALIA)
- HBSAG (ANTIGEN E)
- PLASMA HCG
- URINARY HCG
- HCV-AB ANTI HEPATITIS C
- HDV-AB (ANTIDELTA ANTIBODY)
- HDV-AB IGM
- HDV-AG (DELTA ANTIGEN)
- HPL
- SPECIFIC IGE (FOR ALLERGEN)
- TOTAL IGE (ECL)
- IGG SPECIFICATIONS (PER ALLERGEN)
- IGG4 SPECIFICATIONS (FOR ALLERGEN)
- BASAL INSULIN (ECL)
- MILK (EXAMINATION)
- LACTICODEHYDROGENASE (LDH)
- LH - 2nd WITHDRAWAL
- LH (ECL)
- NSE (ECL)
- OSTEOCALCIN (ECL)
- P.A.P (RIA)
- P.S.A. (ECL)
- PAP TEST (ONCOCITOLOGICAL EXAMINATION)
- PEPTIDE C
- PEPTIDE C - 2nd SAMPLE
- URINARY PEPTIDE C
- PLATELETS
- POTASSIUM
- POTASSIUM
- GLYCEMIC PROFILE
- INSULINEMIC PROFILE (ECL)
- PROGESTERONE (ECL)
- PROLACTIN
- PROLACTIN - 2nd SAMPLE
- TOTAL PROTIDEMIA
- PROTIDOGRAM WITH PROTIDEMIA
- PTH-INTACT (ECL)
- PTH-MN
- RA-TEST
- PAUL BUNNEL REACTION
- WAALER ROSE REACTION
- RENIN (IRMA)
- RENIN (IRMA) - 2nd WITHDRAWAL
- GLOBULAR RESISTANCE
- RETICULOCYTES
- SIDEREMIA
- SERODIAGNOSIS OF V. AND W.
- SODIEMIA NA
- SODIURIA
- SOMATOMEDIN C - 2nd SAMPLE
- SOMATOMEDIN C (ICF - 1) MG / ML
- TA4 (SCC)
- PHARYNGEAL SWAB WITH ANTI BIOGRAM
- NASAL SWAB WITH ANTI BIOGRAM
- TAS
- TBG (RIA)
- DIRECT COOMBS TEST
- INDIRECT COOMBS TEST
- URINARY TESTOSTERONE
- THYROGLOBULIN (ECL)
- TPA
- URINARY TPA
- TRANSAMINASE - GOT (37°)
- TRANSAMINASE - GPT (37°)
- TRICHOMONAS VAGINAL SECRETION
- TRIGLYCERIDES
- TSH (ECL)
- TSH (ECL) - 2nd WITHDRAWAL
- URICOEMIA
- URINE
- URINE CULTURE WITH ANTI BIOGRAM
- ESE
- VES (KATZ INDEX)
- VITAMIN B12 (ECL)

The waiting times for booking and for the collection of reports and attachments of clinical analysis services provided under the accreditation regime with the NHS are shown in the following table:

Waiting times for clinical analysis under accreditation with the NHS – General Basic Laboratory	
Performance	Waiting time for the report
CLINICAL CHEMISTRY, COAGULATION AND HEMATOLOGY	Same day
HOMONOLOGY (thyroid, fertility, tumor markers, hepatitis B markers)	2 days
IMMUNOLOGY (TORCH, AIDS, HCVAB)	3 days
ALLERGOLOGY	5 days
MICROBIOLOGY AND PARASITOLOGY	Depending on the timing of cultivation

Private clinical analysis services provided

- 11 DEOXYCORTISOL
- 13C UREA BREATH TEST FOR H. PYLORI
- 3ALPHA-ANDROSTANEDIOL
- 3ALFA-ANDROSTANEDIOL - 2nd WITHDRAWAL
- AB ANTI - ADENOVIRUS IGG
- AB ANTI - ADENOVIRUS IGM
- AB ANTI - AMOEBA
- AB ANTI - BORRELIA (IGG) - ITALY
- AB ANTI - BORRELIA (IGM)
- AB ANTI - CARDIOLIPIN (IGG + IGM)
- AB ANTI - CYTOMEGALOVIRUS (IGG + IGM)
- AB ANTI - CHLAMYDIA (IGA)
- AB ANTI - CHLAMYDIA (IGG)
- AB ANTI - CHLAMYDIA (IGM)
- AB ANTI - CHLAMYDIA PNEUMONIA (IGA)
- AB ANTI - CHLAMYDIA PNEUMONIA (IGG)
- AB ANTI - CHLAMYDIA PNEUMONIA (IGM)
- AB ANTI - CHLAMYDIA TRACHOMATIS - IGA
- AB ANTI - CHLAMYDIA TRACHOMATIS - IGG
- AB ANTI - CHLAMYDIA TRACHOMATIS - IGM
- AB ANTI - COXACKIE A - TOTAL IGG
- AB ANTI - COXACKIE A4
- AB ANTI - COXACKIE A7
- AB ANTI - COXACKIE A9
- AB ANTI - COXACKIE B - TOTAL IGG
- AB ANTI - COXACKIE B1
- AB ANTI - COXACKIE B2
- AB ANTI - COXACKIE B3
- AB ANTI - COXACKIE B4
- AB ANTI - COXACKIE B5
- AB ANTI - COXACKIE B6
- AB ANTI - COXACKIE VIRUS A - TOTAL GI
- AB ANTI - COXACKIE VIRUS B - TOTAL GI
- AB ANTI - ECHINOCOCCUS
- AB ANTI - ECHO VIRUS - TOTAL GI
- AB ANTI - ECHO VIRUS 11
- AB ANTI - ECHO VIRUS 14
- AB ANTI - ECHO VIRUS 16
- AB ANTI - ECHO VIRUS 18
- AB ANTI - ECHO VIRUS 20
- AB ANTI - ECHO VIRUS 25
- AB ANTI - ECHO VIRUS 28
- AB ANTI - ECHO VIRUS 3
- AB ANTI - ECHO VIRUS 4
- AB ANTI - ECHO VIRUS 6
- AB ANTI - ECHO VIRUS 8
- AB ANTI - ECHO VIRUS 9
- AB ANTI - EPSTEIN BARR NUCLEAR AG
- AB ANTI - EPSTEIN BARR VCA
- AB ANTI - EPSTEIN BARR VIRUS IGG
- AB ANTI - EPSTEIN BARR VIRUS IGM
- AB ANTI - H. PYLORI IGG
- AB ANTI - PARAINFLUENZA TYPE 1
- AB ANTI - PARAINFLUENZA TYPE 2
- AB ANTI - PARAINFLUENZA TYPE 3
- AB ANTI - TYROSINE PHOSPHATASE
- AB ANTI-GASTRIC P. CELLS
- AB ANTI-CENTROMERE
- AB ANTI-CYTOPLASM NEUTROF
- AB ANTI-CYTOPLASM NEUTROPHILS
- AB ANTI-SKIN
- AB ANTI-DNA
- AB ANTI-DNA DS
- AB ANTI-DNA NATIVE
- AB ANTI-DNA SS
- AB ANTI-ENDOMISIO IGA
- AB ANTI-ENDOMISIO IGG
- AB ANTI-ENDOTHELIUM
- AB ANTI-PHOSPHOLIPIDS
- AB ANTI-GAD
- AB ANTI-GLIADIN (IGA)
- AB ANTI-GLIADIN (IGG)
- AB ANTI-H. PYLORI IGA
- AB ANTI-HERPES TYPE 1 IGG
- AB ANTI-HERPES TYPE 1/2 IGM
- AB ANTI-INSULAE PANCREATIC
- AB ANTI-JALURONIDASE
- AB ANTI-LEGIONELLA PNEUMOPHILA
- AB ANTI-LEISHMANIA
- AB ANTI-LEPTOSPIROSIS (TOTAL GI)
- AB ANTI-MALARIA
- AB ANTI-MYCOPLASMA IGG
- AB ANTI-MYCOPLASMA IGM
- AB ANTI-MYCOPLASMA PNEUMONIAE IGG
- AB ANTI-MYCOPLASMA PNEUMONIAE IGM
- AB ANTI-MYELOPEROSSIDASE IGG
- AB ANTI-MITOCHONDRIA
- AB ANTI-MEASLES IGG
- AB ANTI-MEASLES IGM
- AB ANTI-MUCOGASTRIC
- AB ANTI-SPECIFIC KINASE MUSCLE
- AB ANTI-SMOOTH MUSCLE
- AB ANTI-STRIATED MUSCLE
- AB ANTI-CORE
- AB ANTI-CORE IGM
- AB ANTI-OVAIO
- AB ANTI-PAPOVA VIRUS
- AB ANTI-MUMPS IGG
- AB ANTI-MUMPS IGM
- AB ANTI-PARVOVIRUS B19 IGG
- AB ANTI-PARVOVIRUS B19 IGM
- AB ANTI-PERTUSSE IGG

- AB ANTI-PERTUSSE IGM	- URINARY ARSENIC	- BLOOD DICHLOROMETHANE
- AB ANTI-PLATELETS	- THIRD ANTITHROMBIN ACTIVITY	- URINARY DICHLOROMETHANE
- AB ANTI-POLIO	- URINARY NITROGEN	- DI-DIMER
- AB ANTI-PROTEINASE 3 IGG	- KOCH'S BACILLUS (PCR)	- MYOTONIC DYSTROPHY
- AB ANTI-ACETYLCHOLINE RECEPTOR	- BETA – THALASSEMIA (23 MUTATIONS)	- DUCHENNE MUSCULAR
- AB ANTI-TSH RECEPTOR	- BETA-2 BLOOD MICROGLOBULIN	- DYSTROPHY/BECKER (SCREENING I LEVEL)
- AB ANTI-REO VIRUS	- BETA-2 URINARY MICROGLOBULIN	- FETAL HEMOGLOBIN DOSAGE
- AB ANTI-RETICOLINE	- BETA HCG FREE	- HBA2 DOSAGE
- AB ANTI-RIBOSOME	- BICARBONATE	- URINARY AMPHETAMINE DRUGS
- AB ANTI-RNA PROTEINS	- BORDETELLA PERTUSSIS (CROP)	- URINARY BARBITURATE DRUGS
- AB ANTI-RUBELLA IGG	- BRAF (V600E)	- URINARY BENZODIAZEPINE DRUGS
- AB ANTI-RUBELLA IGG-IGM	- BRCA1 (FULL GENE)	- URINARY CANNABINOID DRUGS
- AB ANTI-RUBELLA IGM	- BRCA2 (FULL GENE)	- URINARY COCAINE DRUGS
- AB ANTI-ROTA VIRUS	- BTA (BLADDER TUMOR ANTIGEN)	- URINARY MDMA DRUGS
- AB ANTI-SPERM (L. SEMINAL)	- C-1 Q	- URINARY METHADONE DRUGS
- AB ANTI-STREPTOKINASE	- C-3	- URINARY METHAMPHETAMINE DRUGS
- AB ANTI-SURRENE	- C-4	- URINARY OPIATE DRUGS
- AB ANTI-TOXOPLASMA IGA	- CA 27-29	- DRUGS ON KERATIN MATRIX
- AB ANTI-TOXOPLASMA IGG	- CA 72-4 (ECL)	- DRUGS ON KERATIN MATRIX:
- AB ANTI-TOXOPLASMA IGG-IGM	- CADMIUM IN THE BLOOD	- BARBITURATES
- AB ANTI-TRANSGLUTAMINASE IGA	- CADMIUM IN THE URINE	- KERATIN MATRIX DRUGS: AMPHETAMINES
- AB ANTI-TRANSGLUTAMINASE IGG	- FE BINDING CAPACITY (TIBC)	- KERATIN DRUGS: BENZODIAZEPINES
- AB ANTI-VARICELLO ZOSTER IGG	- CARBAMAZEPINE	- KERATIN DRUGS: CANNABINOIDS
- AB ANTI-VARICELLO ZOSTER IGM	- CARBOXYHEMOGLOBIN	- KERATIN DRUGS: COCAINE
- AB ANTI-VIRUS INFLUENZA A	- MOLECULAR KARYOTYPE (ARRAY- CGH)	- KERATIN MATRIX DRUGS: MDMA
- AB ANTI-VIRUS INFLUENZA B	- CARNITINE	- KERATIN MATRIX DRUGS: METHADONE
- AB ANTI-VIRUS R. SYNCYTIAL	- CARNITINE (L. SEMINAL)	- KERATIN DRUGS: OPIATES
- AB SACCHAROMYCES CEREVISIAE IGA	- FRACTIONAL CATECHOLAMINES	- ECFR (EXONS 18-19-20-21)
- AB-ANTI-SM (SMITH ANTIGEN)	- PLASMA CATECHOLAMINES	- HEMOGLOBIN ELECTOPHORESIS
- ACE	- TOTAL CATECHOLAMINES - URINE 24H	- URINARY PROTEIN ELECTOPHORESIS
- URINARY ACE	- CELIAC DISEASE (DQ2/DQ8)	- PLATELET HEMATOCRIT
- BILE ACIDS	- CERULOPLASMIN	- HEMOCHROMATOSIS 15 MUTATIONS
- 5 - HYDROXYNDOLACETIC ACID	- QUINIDINE	- HEMOCHROMATOSIS (H63D, S65C, C282Y)
- CITRIC ACID - SEMINAL FLUID	- CHLAMYDIA TRACHOMATIS	- GLYCOSYLATED HEMOGLOBIN (HBAIC)
- FETYL-GLYCOXYLIC ACID	- CYSTATIN C	- FECAL EOSINOPHILS
- HYPURIC ACID	- CYSTINE IN THE URINE	- EOSINOPHILS IN URINE
- LACTIC ACID	- CYTOMEGALOVIRUS (PCR)	- HEPATO QUICK
- MANDELIC ACID	- CITRATURIA	- EPSTEIN BARR
- URINARY METHYL-HYPURIC ACID	- CLAMYDIA (IMMNOCHROMATOGRAPHY)	- I QUOTE EXAMINATION. - NEEDLE
- HOMODANILIC ACID	- CLAMYDIA TRACHOMATIS (PCR)	- ASPIRATION
- VALPROIC ACID	- CLEARANCE OF OXALATES	- I QUOTE EXAMINATION. - NEEDLE
- VANYLMADELIC ACID	- URATE CLEARANCE	- ASPIRATION 2nd SAMPLE
- PLASMA ADENOSINEMOPHOSPHATE-C	- PHOSPHATE CLEARANCE	- CYTOLOGICAL EXAMINATION - SECRETION
- URINARY ADENOSINEMOPHOSPHATE-C	- CREATININE CLEARANCE	- CYTOLOGICAL EXAMINATION - SECRETION
- COLD AGGLUTININS	- UREA CLEARANCE	- 2nd SAMPLE
- PLATELET AGGREGATION	- CLOSTRIDIUM (CULTURE)	- URINE CYTOLOGICAL EXAMINATION
- SPONTANEOUS AGGREGATION	- CLOSTRIDIUM DIFFICILE	- CYTOLOGICAL EXAMINATION - EFFUSION
- WING D	- PLASMA COBALT	- CYTOLOGICAL EXAMINATION - POURING
- URINARY WING	- ESTERIFIED CHOLESTEROL	- 2nd SAMPLE
- ALBUMINEMIA	- HDL CHOLESTEROL	- CYTOLOGICAL EXAMINATION LIQUID
- URINARY ALCOHOL	- LDL CHOLESTEROL	- PHASE
- ALCOHOLEMIA	- VLDL CHOLESTEROL	- HISTOLOGICAL EXAMINATION - 1st
- ALPHA ANTITRYPSIN	- CHOLINESTERASE (37°)	- SAMPLE
- SERUM ALUMINIUM	- IN VITRO INTESTINAL MUCOSA CULTURE	- ASCITIC FLUID EXAMINATION
- URINARY ALUMINIUM	- TOTAL COMPLEMENT	- CEPHALO-RACHIDIAN FLUID
- AN. MARKER MICROSATELLITES LHO/RER	- CONTA DI ADDIS	- EXAMINATION
- K-RAS GENE MUTATION ANALYSIS	- COPROPORPHYRINS	- PERITONEAL FLUID EXAMINATION
- FRAGMENT ANALYSIS	- COTININ TEST	- PLEURAL FLUID EXAMINATION
- BRCA2 GENE MUTATION ANALYSIS	- COVIG SARS-COV-2-IGG	- SYNOVIAL FLUID EXAMINATION
- BRCA1 GENE MUTATION ANALYSIS	- COVIM-SARS-COV2-IGM	- SECRETORY EXAMINATION AT FRSSCO
- MLH1 GENE MUTATION ANALYSIS	- COV2 ANTI SARS COV2 IG TOTAL	- ULTRASTRUCTURAL MICROSCOPY
- MUTATION ANALYSIS OF THE MSH2 GENE	- COV2R ANTI SARS COV2 IG TOTAL REFLEX	- EXAMINATIONS
- MUTATION ANALYSIS OF THE RET	- CREATINE PHOSPHOKINASE (CPK)	- TOTAL ESTROGENS
- PONCOGENE	- CREATINURIA	- ETHOSUCCIMIDE
- SEQUENCE ANALYSIS	- CREATINURIA - 2nd SAMPLE	- F.A.G.
- CYST FIBROSIS GENE SEQUENCE ANALYSIS	- CRYOAGGLUTININS	- F.D.P. URINARY
- MSH2 AND/OR MLH1 SEQUENCE ANALYSIS	- CRYOGLOBULINS	- FACTOR II* MUTAZ. PROTHROMBIN GENE
- MUTATION SEQUENCE ANALYSIS IN RET	- CHROMIUM IN THE BLOOD	- FACTOR V - Y1702C
- ANDENOVIRUS IN FECES (RESEARCH)	- CHROMIUM IN THE URINE	- COAGULATIVE FACTOR V
- ANEUPLOIDIES ON ABORTIVE MATERIAL	- CHROMOGRANIN A	- FACTOR V* - POLYMORPHISM H 1299 R
- ANEUPLOIDIES QF - PCR 21 - X-Y	- URINARY CROSS LAPS	- FACTOR V* OF LEIDEN
- ANEUPLOIDIES QF - PCR 21 - X-Y - 18 -13	- CROSS LAPS-TELOPEPTIDE C TERMINAL	- COAGULATIVE FACTOR VII
- PLATELET ANTGENE HPA - 1	- URINARY CROSS LINKS (PMOLI/IMMOLI)	- COAGULATIVE FACTOR VIII
- ANTI IA2	- CUPREMIA	- THROMBOTIC FACTORS (14 MUTATIONS)
- ANTIDIURETIN	- CUPRURIA	- THROMBOTIC FACTORS (6 MUTATIONS)
- EXTRACTABLE NUCLEAR ANTIGEN	- CYFRA 21 (ECL)	- PHENYTOIN
- HAPLOTYPY Y	- CYTO-TEST (50 FOODS)	- PHENOBARBITAL
- APOA1	- CYTO-TEST (51 MIX)	- URINARY PHENOLS
- APOLIPOPROTEIN B	- DEPAKIN	- SICKLE CELL PHENOMEMO
- HAPTOGLOBIN	- AVERAGE CORPUSCULAR DIAMETER	- CYSTIC FIBROSIS (WHOLEGENE)

- CYSTIC FIBROSIS SCREENING 36 MUTATIONS
- CYSTIC FIBROSIS SCREENING 57 MUTATIONS
- BLOOD FLUORINE
- SEMINAL FLUID ACID PHOSPHATASE
- PLACENTAL ALKALINE PHOSPHATASE
- THERMOSTABLE ALKALINE PHOSPHATASE
- PHOSPHOHEXOSE ISOMERASE
- PHOSPHOLIPIDS
- FREE TESTOSTERONE
- FREE TESTOSTERONE - 2nd WITHDRAWAL
- FRUCTOSAMINE
- FRUCTOSE IN SEMINAL FLUID
- FSH (ECL)
- FTA - ABS
- FTA - ABS IGM
- G6PDH
- GENOTYPE X
- ANAEROBIC GERMS (CROP RESEARCH)
- GLYCERYLPHOSPHORYLCHOLINE
- FRACTIONAL GLYCOSURIA (G/L)
- GONOCOCCUS-NEIS. GONORRHOEAE (PCR)
- GONOCOCCUS-NEIS. GONORRHOEAE 2* (PCR)
- BLOOD TYPE RH FACTOR
- HAEMOPHILUS
- HBDH
- HBV (QUALITATIVE)
- HBV(QUA NTITATIVO)
- HBV TYPING (PCR)
- HBV-DNA (PCR) (QUALITATIVE)
- HCV (QUALITATIVE)
- HCV (QUANTITATIVE)
- HCV TYPING - GENOMIC RESEARCH
- HCV-AB IGM
- HCV-RNA (QUALITATIVE)
- HELICOBACTER P. RESEARCH AG ON FECES
- HERPES VIRUS 1/2
- HIV 1+2 (IV GENERATION ELFA)
- QUANTITATIVE HIV
- QUALITATIVE HIV
- HIV WESTERN BLOT
- HLA - LINF TYPING. HLA (DR+DQ)
- HLA CLASS A GENOMIC TYPING
- HLA CLASS B GENOMIC TYPING
- HLA CLASS C GENOMIC TYPING
- HLA FOR BECHET
- HLA FOR TYPE 1 DIABETES
- HLA FOR NARCOLEPSY
- HLA FOR PSORIASIS
- HLA FOR ANKYLOSING SPONDYLITIS
- HLA FOR UVEITIS
- HLA-A
- HLA-B
- HLA-C
- HLA I CLASS
- HLA II CLASS
- HLA I and II CLASS
- HPV RNA (PCR)
- HPV TYPING (PCR)
- HTLV 1/2
- KRAS (CODON 12-13-61)
- URINARY HYDROXYPYRENE (END OF SHIFT)
- HYDROXYPROLINURIA (M. OF ZENDER)
- IMMNOELECTROPHURESIS
- LYMPHOCYTE HYMMNOPHENOTYPING
- CIRCULATING IMMUNOCOMPLEXES
- URINARY IMMUNOELECTROPHYSIS
- IMMUNOGLOBULINS - IGG 1
- IMMUNOGLOBULINS - IGG 2
- IMMUNOGLOBULINS - IGG 3
- IMMUNOGLOBULINS - IGG 4
- IMMUNOGLOBULIN A
- IMMUNOGLOBULIN D
- IMMUNOGLOBULIN G
- IMMUNOGLOBULINS G- SUBCLASSES
- IMMUNOGLOBULIN N
- SALIVARY IMMUNOGLOBULINS IGA
- IMMUNOSUPPRES. ACIDIC PROTEIN
- INACTIVATOR C-1 ESTERASE
- INIBIN B
- INSTABILITA' MICROSATELLITES
- FOOD INTOLERANCE (181 ALIM.)
- FOOD INTOLERANCE (94 ALIM.)
- URINARY IODINE (MCG/L)
- HYPOCHONDROPLASIA
- CREATINE KINASE ISOENZYME
- ALKALINE ISOENZYME PHOSPHATASE
- ISOENZYMES OF ISYLASE
- JO - 1 (AB - ANTI JO1)
- JAK2
- LACTASE
- URINARY LACTOSE
- LDH - ISOENZYMES
- LEUCINOAMINOPEPTIDASE (LAP)
- CD3/INTRAEPITHELIAL LYMPHOCYTES
- CD3 /INTRAEPITHELIAL LYMPHOCYTES + ISTOL
- LIPASEMIA
- LIPEMIA
- LIPIDOGRAM
- SEMINAL FLUID (EXAMINATION)
- LISTERIA (CROP)
- LISTERIA MONOCYTCA - 4 AG
- LITIEMIA (LT) - ITALY
- LKM
- ANTI-COAGULANT LUPUS
- MACRODELETIONS CYSTIC FIBROSIS GENE
- MAGNESEMIA
- INTRASRYTHROCYTE MAGNESIUM
- URINARY MAGNESIUM
- MANGANESE
- URINARY MANGANESE
- CHROMOSOMAL MAP
- MCH (AVERAGE HB CONTENT)
- MCHC (CONTENT HB CORP. AVERAGE)
- MCV (AVERAGE GLOBULAR VOLUME)
- MLH1 (WHOLE GENE)
- MLH2 (WHOLE GENE)
- MTHFR (A1298C)
- MTHFR (C677T)
- URINARY MELANIN
- FAMILIAL AND/OR MULTIPLE MELANOMA (CDKN2A,P14, CDK4) ENTIRE GENES
- MERCURY
- URINARY MERCURY
- METHEMOGLOBIN
- PLASMA METHANEPHRINE
- URINARY METHANEPHRINE
- TUBERCULOUS MYCOBACTERIUM
- MYCOPLASMA HOMINIS (PCR)
- MYCOPLASMA (CULTURAL RESEARCH)
- MICROALBUMINURIA
- Y CHROMOSOME MICRODELETIONS
- MILGRAM TOWDER
- SERUM MYOGLOBINS
- MONONUCLEOSIS (TEST)
- MUCOPROTEINS
- NEFA
- NEISSERIA GONORRHOEAE
- FECAL NEUTROPHILS
- NICKEL IN THE BLOOD
- NICKEL IN THE URINE
- N-N-DIMETHYLFORMAMIDE
- NORMETANEPHRINE
- NORMOTEST
- NRAS (CODON 12-13-61)
- DIBUCAINE NUMBER
- HOMOCYSTEINE
- URINARY HOMOCYSTEINE
- ONYCHOMYCOSIS DIRECT RESEARCH
- ONCOCHECK
- URINARY OSMOLARITY
- OXALEMIA
- OXALLURIA
- QF PCR (13-18-21-X-Y)
- P.S.A. FREE (ECL)
- P53 WHOLE GENE
- PA - PAI GENE POLYMORPHISM - 1
- TRADITIONAL PAP SMEAR
- PAPP-A
- ALLELIC PATTERN
- PHADIATOP (CAP SYSTEM)
- LEAD
- LEAD IN URINE
- PYRUVATE ERYTHROCYTE KINASE
- PLASMINOGEN
- PLASMODIUM MALARIAE (RESEARCH)
- POLYMORPHISM A1298C (MTHFR)
- POLYMORPHISM A1298C + C677T (MTHFR)
- POLYMORPHISM C677T (MTHFR)
- URINARY PORPHYINE
- PORFOBILIGENO
- PRENETAL SAFE (VARIOUS LEVELS)
- PRIME-TEST (50 FOODS)
- PRIME-TEST (CYTOTOXIC)
- PRIMIDONE
- PROCALCITONIN
- BRAIN NATRIURETIC PROPEPTIDE
- PROTEIN C (COAGULATIVE)
- PROTEIN S (COAGULATIVE)
- C.R. PROTEIN (QUANTITATIVE)
- EOSINOPHIL CATIONIC PROTEIN
- PROTEIN P16
- URINARY PROTEIN
- URINARY PROTEIN - 2nd sample
- PROTEINURIA DI BENCE-JONES
- CONCENTRATION TEST
- DILUTION TEST
- HEMOGENIC TESTS
- PTT
- STEINIZ QUOTIENT
- R.P.R. (RAPID PLASMA REAGIN)
- CAU RATIO (++) / CREATININURIA
- INBREEDING RELATIONSHIP X LINKED
- INBREEDING RELATIONSHIP Y LINKED
- GHEDINI REACTION - WEINBERG
- HANGER REACTION
- KUNKEL REACTION
- WEIL-FELIX REACTION
- WUNDERLI REACTION
- SOLUBLE TRANSFERRIN RECEPTOR
- ESTROGENIC RECEPTORS - PREGESTINS
- ACTIVATED PROTEIN C RESISTANCE
- CLOT RETRACTION
- REVISION ISTOL/CITOL/AGOC/ESTRERNI
- RNP (AB ANTI RIBONUCLEOPROTEINS)
- ROSETTE E
- ROTA VIRUS IN FECES (RESEARCH)
- RUBELLA (ONLY ON BLOOD)
- RUBELLA VIRUS (PCR) GENOME SEARCH
- S100 (ECL)
- SALICYLATE
- TRANSFERRIN SATURATION
- ARNETH DIAGRAM
- SCOTH TEST
- SCOTH TEST - 2nd SAMPLE
- SCOTH TEST - 3rd SAMPLE
- SEROTONIN (URINE 24H)
- BLOOD SEROTONIN
- SHBG
- SHIGELLA (CULTURE IN FECES)
- SIDERURIA
- GILBER SYNDROME (UGT1A1 GENE POLYMORPHISM)
- CONGENETIC DEAFNESS (WHOLE GJB2 GENE)
- CONGENETIC DEAFNESS (SCREENING OF MAJOR GJB2 GENE MUTATIONS)
- SM (AB-ANTI SM)
- STREPTO M-TEST
- STREPTOZYME TEST
- SWIM - UP
- T.P.H.A.
- T3 (ECL)
- T3 UPTAKE
- T4 (ECL)
- TAF

- | | | |
|-----------------------------|--------------------------------------|--------------------------------------|
| - TAN TG ANTIGENIC BUFFER | - TISSUE LYMPHOCYTE TYPING | - TROPONIN |
| - TCA (TRICHOACETIC ACID) | - LYMPHOPROLIFERATIVE TYPING | - UREAPLASMA UREALITICUM (PCR) |
| - TCE (TETRACHLOROETHYLENE) | - TYPING EPITHELIAL NEOPLASIA | - URICURIA |
| - TELOPEPTIDE - URINE | - TOXOPLASMA GONDII (PCR) | - UROPORPHYRINS |
| - HOWELL'S TIME | - TRANSFERRIN | - V.D.R.L. |
| - XYLOSE TEST | - CARBOHYDRATE DEFICIENT TRANSFERRIN | - VARICELLA ZOSTER (PCR) |
| - RUBELLA AVIITY TEST (IGG) | - UNSATURATED TRANSFERRIN | - VITAMIN D3 |
| - PREGNANCY TEST | - TREPONEMA PALLIDUM | - VITAMIN E |
| - TEST DI NORDIN | - TRICHOMONAS SEMINAL FLUID | - MEDIUM PLATELET VOLUME |
| - TEST DI SIA | - TRICHOMONAS IN URINE | - XILOSEMIA |
| - TEST DI SINGER-PLATZ | - TRICHOMONAS CERVICAL SECRETION | - X FRAGILE |
| - ECHINOCOCCUS TEST | - TRICHOMONAS PROSTATE SECRETION | - YERSINIA 2nd CAMP. (STOOL CULTURE) |
| - FOOD GENETIC TESTING | - TRICHOMONAS SECRETORY URETHRAL | - YERSINIA 3rd CAMP. (STOOL CULTURE) |
| - GENETIC TEST FOR ALOPECIA | - TRI-TEST | - ZINC |
| - RAPID TEST FOR SBEA | - THROMBOPHILIA 5 GENETIC FACTORS | - URINARY ZINC |
| - URINARY THIOCYANATES | - THROMBOPHILIA 6 GENETIC FACTORS | - ZINCPROTOPORPHYRIN |


It is possible to request information from the secretariat about any further examinations introduced after the issuance of this service card.

The waiting times for booking and for the collection of reports and attachments relating to clinical analysis services provided in a private regime are shown in the following table:

Waiting times for clinical analysis in private	
Performance	Waiting time for the report
CLINICAL CHEMISTRY, COAGULATION AND HEMATOLOGY	Same day
HOMONOLOGY (thyroid, fertility, tumor markers, hepatitis B markers)	2 days
IMMUNOLOGY (TORCH, AIDS, HCVAB)	3 days
ALLERGOLOGY	5 days
MICROBIOLOGY AND PARASITOLOGY	Depending on the timing of cultivation
MOLECULAR BIOLOGY	7 days - 30 days
CITO GENETICS (karyotype, Arry CGH)	7 days - 20 days
CYTO-ISTO PATHOLOGY	15 days

8. LOCATION AND CONTACT DETAILS

U.S.I. Numidio Quadrato is located in Rome in Via Tuscolana 703 (Numidio Quadrato area) and is easily accessible via A (Fermata Numidio Quadrato) and the countless bus lines that run along Via Tuscolana.



WEBSITE: www.usi.it

EMAIL: info@usi.it

TELEPHONE NUMBERS:

- USI single number for acceptances and reservations: **06 32868.1**
- Health Directorate: 06 32868.334
- Public Relations Office (URP): 06 32868.333

9. OPENING DAYS AND HOURS

Opening Center	Levies	Withdrawal of Reports
Monday – Saturday: 07.00-13.00	Monday – Saturday: 7.00-11.00	Monday – Saturday 11.00-13.00